Early Detection Works
Generally, if we find cancer early, 90 percent survive. If we find cancer late, 10 percent survive. Earlier detection leads to earlier, more precise treatment that can treat and cure cancer.
However, there are few effective early detection methods for cancer. We're here to change that.
Survival (%) Correlated with Stage of Diagnosis
How We're Different
We've taken an "out-of-the-box" approach to detecting cancer. Today, most laboratories rely on the overall expression of biomarkers. These biomarkers, often proteins, are typically upregulated in the context of cancer. However, it has become clear that a number of non-cancerous conditions can also cause an upregulation of these biomarkers. Therefore, false positives are very common. For example, PSA, which is the biomarker used for prostate cancer, can also be upregulated due to inflammation, benign prostatic hyperplasia, urinary tract infection, and even something as common as riding a bike.
Our approach to detecting cancer at the earliest stage is to determine not just the overall expression of these biomarkers, but rather their origin. We have developed proprietary technology that determines whether a specific biomarker was produced by normal cells or cancer cells.